Verrica Pharmaceuticals Inc.
VRCA
$6.73
-$0.82-10.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 234.73% | 5.72% | -19.45% | 47.66% | 187.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 234.73% | 5.72% | -19.45% | 47.66% | 187.45% |
| Cost of Revenue | -44.68% | -56.57% | -53.89% | -30.71% | -0.86% |
| Gross Profit | 325.35% | 159.58% | 73.81% | 55.94% | 40.20% |
| SG&A Expenses | -43.91% | -37.55% | -13.47% | 24.35% | 96.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.08% | -42.15% | -25.22% | 7.40% | 62.03% |
| Operating Income | 78.27% | 50.65% | 25.91% | -4.14% | -53.81% |
| Income Before Tax | 69.39% | 44.09% | 18.27% | -14.31% | -75.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.39% | 44.09% | 18.27% | -14.31% | -75.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.39% | 44.09% | 18.27% | -14.31% | -75.92% |
| EBIT | 78.27% | 50.65% | 25.91% | -4.14% | -53.81% |
| EBITDA | 78.76% | 51.04% | 26.35% | -3.52% | -53.59% |
| EPS Basic | 81.16% | 55.79% | 31.22% | -5.04% | -69.91% |
| Normalized Basic EPS | 80.65% | 54.53% | 29.06% | -9.04% | -64.82% |
| EPS Diluted | 81.16% | 55.80% | 31.19% | -5.07% | -69.59% |
| Normalized Diluted EPS | 80.65% | 54.53% | 29.06% | -9.04% | -64.82% |
| Average Basic Shares Outstanding | 89.11% | 63.91% | 38.25% | 14.22% | 5.67% |
| Average Diluted Shares Outstanding | 89.13% | 63.93% | 38.25% | 14.22% | 5.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |